Literature DB >> 15864213

[Oxaliplatin neurotoxicity: a report of three cases with post-operative exacerbation].

Agnès Cournede1, Pauline Ries, Karine Richard, Alexandra Guillain, Laëtitia Dahan, Philippe Grandval, Bertrand Pourroy, Vincent Moutardier, Jean Hardwigsen, Diane Braguer, Jean-François Seitz.   

Abstract

Liver metastases of colorectal cancer are rarely rapidly resectable. The efficacy of new chemotherapy regimen, in particular the combination of 5FU and oxaliplatin make further surgical resection possible in the case of an objective response in some patients. Three patients with metastatic colorectal cancer received oxaliplatin-based chemotherapy; only minimal and transient neurosensory toxicity occurred. After a partial response to treatment, surgical resection of metastases was performed. Patients reported major exacerbation of oxaliplatin-induced neurosensory toxicity following surgery (between day 7 and day 15). One patient experienced sensory loss of the extremities with functional impairment (grade 3 on Levi's scale). The symptoms persisted for 812 months after surgery in the three patients. Only seven similar cases have been reported. Toxicity could be associated with the concentration of oxaliplatin in the red blood cells: oxaliplatin binds irreversibly to erythrocytes. This exacerbation could be the consequence of peroperative hemolysis with a redistribution of the pool of intra-erythrocytic oxaliplatin biotransformation products into the plasma. We did not find any relationship with anesthesic or per-operative medications. Studies are necessary to define the precise mechanism and the frequency of this reaction.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15864213     DOI: 10.1016/s0399-8320(05)80817-6

Source DB:  PubMed          Journal:  Gastroenterol Clin Biol        ISSN: 0399-8320


  1 in total

1.  Neoadjuvant sorafenib combined with gemcitabine plus oxaliplatin in advanced hepatocellular carcinoma.

Authors:  Nicolas Williet; Olivier Dubreuil; Tarek Boussaha; Isabelle Trouilloud; Bruno Landi; Martin Housset; Muriel Botti; Philippe Rougier; Jacques Belghiti; Julien Taieb
Journal:  World J Gastroenterol       Date:  2011-05-07       Impact factor: 5.742

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.